Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II multicentre open label trial evaluating the efficacy and safety of the liopsomal doxorubicin (Myocet) and docetaxel (Taxotere) combination as first-line treatment of patients with metastatic HER2/neu negative breast cancer.

Trial Profile

Phase II multicentre open label trial evaluating the efficacy and safety of the liopsomal doxorubicin (Myocet) and docetaxel (Taxotere) combination as first-line treatment of patients with metastatic HER2/neu negative breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2011

At a glance

  • Drugs Docetaxel (Primary) ; Doxorubicin liposomal (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms MYOTAX
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 18 Nov 2009 Actual number of patients (70) added and trial sponsor changed from Zeneus Pharma to Cephalon as reported by ClinicalTrials.gov
    • 17 Nov 2009 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top